- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Ipsos Extends NASH Therapy Monitor to Japan
Ipsos Healthcare, the global healthcare division of Ipsos, announced it has extended its Global Nonalcoholic Steatohepatitis (NASH) Therapy Monitor to Japan. The NASH Monitor is part of Ipsos’ virology and liver diseases real-world evidence portfolio and is available in the EU5 and U.S.
Ipsos’ new Japanese study will combine real patient data with physician observations to illuminate the NASH market in Japan, allowing for globally comparable data cross-market comparisons. Subscribers can evaluate and size NASH patient segments, understand patient journeys, identify referral patterns and stakeholder involvement, and pinpoint doctors’ expectations on required clinical endpoints for NASH trials.
The new Therapy Monitor complements Ipsos’ existing real-world evidence offer in Japan, which consists of oncology, virology, autoimmune, and cardiovascular diseases.
Dr. Sabina Heinz, Ipsos’ Director of Real World Evidence in Global Diseases commented:
“Although Japan has the lowest rate of obesity in the industrialised world, it is on the rise. Furthermore, theprevalence of fatty liver in Japan has increased over the past 10 years. With both factors contributing to Nonalcoholic Steatohepatitis, we expect to see a growing incidence of the disease in Japan. The Japanese NASH Therapy Monitor will enable our clients, both local and global, to better understand the dynamics of this emerging disease and identify any unmet needs specifically in this market for Japanese patients.”
Hall
William Hall, Head of Ipsos Healthcare Japan, added:
“During the past 20 to 30 years, the frequency of patients presenting with Nonalcoholic Fatty Liver Diseases (NAFLD) has increased gradually in Japan in proportion to the increase in the population with lifestyle-related diseases. The rate of obesity in the population is not high compared to Western countries, but the incidence of NAFLD is similar to those countries. The NASH Therapy Monitor, now covering Japan, EU and U.S., will enable our clients to more clearly understand and respond to these differences.”
